instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
The Kate Spade New York Foundation said in a statement Wednesday it is donating $200,000 to The Jed Foundation, which partners with schools to strengthen mental health programs. The fashion brand will match public donations to JED from Wednesday through June 12, up to $100,000, at jedfoundation.org/katespade. The donations follow money already given to other organizations, including the Crisis Text Line. Anna Bakst, brand president and CEO of Kate Spade New York, said the company hopes to encourage more conversation, education and research around mental health. Spade killed herself June 5, 2018, at 55, after years of battling depression and anxiety.
answer:
Kate Spade New York fulfills $1 million mental health pledge.


question:
Navajo President Jonathan Nez made the announcement after a spike in deaths that he attributed to shifting traffic patterns after the city of Gallup recently shut down to outside visitors. That lockdown in northwestern New Mexico has since ended. On the Navajo Nation, residents will face citations, with potential fines and jail time, if they leave their homes during the lockdown, which starts Friday night and ends Monday around dawn. Nez urged people to listen and not pack their bags to head out of town during the lockdown. “Stay home, that’s the bottom line. There’s nothing wrong with staying home and taking care of your home, taking care of your family members,” a frustrated Nez said Thursday. “We need to be able to recognize that what you do affects everybody.” While the state of Arizona has loosened its restrictions on residents and businesses, the Navajo Nation has clamped down. The tribe already has daily nighttime curfews and requires people to wear masks when out in public. Government offices are closed or have limited services. The tribe’s stay-at-home order has been extended to June 7, while Arizona’s expired Friday. As of Friday, the tribe reported 127 deaths and 3,740 positive coronavirus cases since it first began tracking the figures. More than 500 people have recovered, tribal health officials said. There were no new deaths reported on Friday. Loretta Christensen, the chief medical officer for the Navajo-area Indian Health Service, said the reservation’s three largest hospitals hit capacity last week — in line with expected predictions — and a significant number of patients were transferred off the reservation. “We’re still getting cases across the area, but not at the velocity we did before,” she said in a call with reporters Thursday. People who have tested positive but no longer need to be hospitalized are being encouraged to stay in one of three isolation centers set up in basketball gyms on and off the reservation to protect their families. Isolation tents also are available for those who would rather not leave their property, Christensen said. For most people, the new coronavirus causes mild or moderate symptoms, such as fever and cough that clear up in two to three weeks. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia, and death. McKinley County, which includes Gallup, had been the hot spot on the reservation because of a recent outbreak at a detox center. Apache County in Arizona surpassed it with the most COVID-19 cases on the reservation, according to the Thursday figures. Apache County had 948 positive cases, while McKinley County had 928, tribal officials said. Navajo County in Arizona had 757 cases, and San Juan County in New Mexico had 428. Six other counties in Arizona, New Mexico and Utah had smaller numbers. The Navajo Nation’s total cases include 99 that previously weren’t included because they took longer than usual to verify. Tribal officials also cited jurisdictional challenges.
answer:
Navajo Nation residents to be under strictest lockdown yet.


question:
Merck & Co. voluntarily pulled the blockbuster drug in 2004 amid evidence that it doubled the chances of having a heart attack or stroke. Now tiny Tremeau Pharmaceuticals is working to bring it back, to treat severe joint pain caused by the bleeding disorder hemophilia. That’s for far fewer patients than the millions who took Vioxx pills for arthritis and other chronic pain — but if it’s approved doctors could again legally prescribe it to anyone. Many hemophilia patients rely on opioid painkillers because nearly every other pain reliever increases the risk of internal bleeding. Considerable research shows Vioxx doesn’t do that. “It seemed to me that there was a huge unmet medical need” for these patients, Brad Sippy, Tremeau’s chief executive, told The Associated Press. He put together a plan and co-founded Tremeau last year to develop nonopioid pain treatments for rare diseases. A longtime pharmaceutical marketing executive, Sippy worked at Merck during the Vioxx era and helped with its recall from pharmacy shelves. He also knew the final patent protecting Vioxx’s monopoly was expiring this fall. When it stopped making Vioxx, Merck was facing thousands of lawsuits from people claiming the drug caused their heart attacks or strokes. Merck’s own research showed the drug doubled those risks, but lawyers for patients claimed the company downplayed or concealed that. Merck initially fought the lawsuits but in 2007 agreed to a $4.85 billion settlement. If Tremeau gets approval in a few years to start selling rofecoxib, the chemical name for Vioxx, doctors could prescribe it to other people with garden-variety chronic pain. Tremeau wouldn’t be able to legally promote those unapproved uses, but some patients likely would want it. Vioxx was so effective that some users hoarded it after Merck took it off market. “I know a lot of people who swore by Vioxx,” said analyst Steve Brozak, president of WBB Securities. “Repurposing this for the hemophilia community is particularly brilliant.” Dr. Steven Stanos, president of the American Academy of Pain Management, a professional group for pain specialists, said it made sense to try Vioxx for hemophilia joint pain. “Vioxx was very potent,” he said. The drug would still carry a strong warning about heart attack and stroke risks. Doctors would have to balance its pain benefit against each patient’s risks, Stanos said. On Tuesday, Tremeau announced that the Food and Drug Administration recently handed it an endorsement of sorts: an orphan drug designation. That’s for disorders affecting fewer than 200,000 Americans, and comes with benefits, including tax credits on testing costs and a free FDA review. Still, it’s no slam-dunk. Sippy said the Cambridge, Massachusetts-based Tremeau must raise $25 million or more to pay for testing in hemophilia patients. Then the results must be good enough for FDA approval. In the U.S., just over 20,000 people have hemophilia, an inherited disorder that leaves them without key proteins in the blood needed for clotting. The slightest injury can trigger uncontrolled internal bleeding. Since the 1990s, most patients have been getting medicine that limits but doesn’t prevent all bleeding episodes. Blood buildup in the joints can damage them and cause pain. “Without other options, opioids are often the next step” after Tylenol, sometimes at high doses, said Dr. Stacy Croteau of the Boston Hemophilia Center, who is a paid consultant for Tremeau. “Rofecoxib would hopefully allow us to reduce use of opioids.” Meanwhile, Tremeau is deciding on the drug’s brand name. Sippy said the Vioxx name, no longer protected by trademark, might scare some people, while others would remember its effectiveness. “We haven’t excluded it,” he said. ___ Follow Linda A. Johnson at @LindaJ_onPharma
answer:

Startup wants to bring back Vioxx for hemophilia joint pain.